MRS2500 [2-iodo-N6-methyl-(N)-methanocarba-2′- deoxyadenosine-3′,5′-bisphosphate], a potent, selective, and stable antagonist of the platelet P2y1 receptor with strong antithrombotic activity in mice

Journal of Pharmacology and Experimental Therapeutics

Volumn 316, Issue 2, 2006, Pages 556-563

  Hechler, Béatrice ^a,b,c   Nonne, Christelle ^a,b   Eun, Joo Roh ^d   Cattaneo, Marco ^e   Cazenave, Jean Pierre ^a,b,c   Lanza, François ^a,b,c   Jacobson, Kenneth A ^d   Gachet, Christian ^a,b,c  

^a INSERM   (France)

^b ETABLISSEMENT FRANÇAIS DU SANG   (France)

^c UNIVERSITÉ DE STRASBOURG   (France)

^d NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES   (United States)

^e UNIVERSITY OF MILAN   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

15 HYDROXY 11ALPHA,9ALPHA EPOXYMETHANOPROSTA 5,13 DIENOIC ACID; 2 IODO N 6 METHYLMETHANOCARBA 2' DEOXYADENOSINE 3',5' BISPHOSPHATE; ADENOSINE DERIVATIVE; ANTICOAGULANT AGENT; CLOPIDOGREL; MRS 2500; PURINE ANTAGONIST; PURINE P2Y1 RECEPTOR; PURINE P2Y1 RECEPTOR ANTAGONIST; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL TISSUE; ARTERY CALCIFICATION; ARTICLE; BLEEDING TIME; CONTROLLED STUDY; DISEASE SEVERITY; DRUG EFFECT; DRUG INHIBITION; DRUG POTENCY; DRUG POTENTIATION; DRUG RECEPTOR BINDING; DRUG SELECTIVITY; DRUG STABILITY; EX VIVO STUDY; MALE; MOUSE; NONHUMAN; PRIORITY JOURNAL; THROMBOCYTE AGGREGATION INHIBITION; THROMBOCYTE FUNCTION; THROMBOEMBOLISM; THROMBOSIS PREVENTION; VALIDATION STUDY;

ANIMALS; BLOOD PLATELETS; DEOXYADENINE NUCLEOTIDES; DISEASE MODELS, ANIMAL; MALE; MICE; MICE, KNOCKOUT; PLATELET AGGREGATION; PLATELET AGGREGATION INHIBITORS; RECEPTORS, PURINERGIC P2; THROMBOEMBOLISM;

EID: 31144440812     PISSN: 00223565     EISSN: 15210103     Source Type: Journal    
DOI: 10.1124/jpet.105.094037     Document Type: Article

References (33)

1. Baurand A and Gachet C (2003) The P2Y(1) receptor as a target for new antithrombotic drugs: a review of the P2Y(1) antagonist MRS-2179. Cardiovasc Drug Rev 21:67-76.
2. Baurand A, Raboisson P, Freund M, Léon C, Cazenave JP, Bourguignon JJ, and Gachet C (2001) Inhibition of platelet function by administration of MRS2179, a P2Y1 receptor antagonist. Eur J Pharmacol 412:213-221.
3. Bhatt DL and Topol EJ (2003) Scientific and therapeutic advances in antiplatelet therapy. Nat Rev Drug Discov 2:15-28.
4. 6-methyl 2′- deoxyadenosine 3′,5′-bisphosphate. Br J Pharmacol 124:1-3.
5. Cattaneo M, Lecchi A, Ohno M, Joshi BV, Besada P, Tchilibon S, Lombardi R, Bischofberger N, Harden TK, and Jacobson KA (2004) Antiaggregatory activity in human platelets of potent antagonists of the P2Y 1 receptor. Biochem Pharmacol 68:1995-2002.
6. DiMinno G and Silver MJ (1983) Mouse antithrombotic assay: a simple method for the evaluation of antithrombotic agents in vivo. Potentiation of antithrombotic activity by ethyl alcohol. J Pharmacol Exp Ther 225:57-60.
7. Fabre JE, Nguyen M, Latour A, Keifer JA, Audoly LP, Coffman TM, and Koller BH (1999) Decreased platelet aggregation, increased bleeding time and resistance to thromboembolism in P2Y1-deficient mice. Nat Med 5:1199-1202.
8. Foster CJ, Prosser DM, Agans JM, Zhai Y, Smith MD, Lachowicz JE, Zhang FL, Gustafson E, Monsma FJ Jr, Wiekowski MT, et al. (2001) Molecular identification and characterization of the platelet ADP receptor targeted by thienopyridine antithrombotic drugs. J Clin Investig 107:1591-1598.
9. Gachet C, Cattaneo M, Ohlmann P, Hechler B, Lecchi A, Chevalier J, Cassel D, Mannucci PM, and Cazenave JP (1995) Purinoceptors on blood platelets: further pharmacological and clinical evidence to suggest the presence of two ADP receptors. Br J Haematol 91:434-444.
10. Gachet C and Hechler B (2005) The platelet P2 receptors in thrombosis. Semin Thromb Hemostasis 31:162-167.
11. Gingrich JA and Hen R (2000) The broken mouse: the role of development, plasticity and environment in the interpretation of phenotypic changes in knockout mice. Curr Opin Neurobiol 10:146-152.
12. 1 cation channel in thrombosis of small arteries in vivo. J Exp Med 198:661-667.
13. Hechler B, Magnenat S, Zighetti ML, Kassack MU, Ullmann H, Cazenave JP, Evans R, Cattaneo M, and Gachet C (2005) Inhibition of platelet functions and thrombosis through selective or nonselective inhibition of the platelet P2 receptors with increasing doses of NF449. J Pharmacol Exp Ther 314:232-243.
14. Hodivala-Dilke K, McHugh K, Tsakiris D, Rayburn H, Crowley D, Ullman-Cullere M, Ross F, Coller B, Teitelbaum S, and Hynes RO (1999) β3-Integrin-deficient mice are a model for Glanzmann thrombasthenia showing placental defects and reduced survival. J Clin Investig 103:229-238.
15. Jacobson KA, Mamedova L, Joshi BV, Besada P, and Costanzi S (2005) Molecular recognition at adenine nucleotide (P2) receptors in platelets. Semin Thromb Hemostasis 31:205-216.
16. 1 receptor antagonist. Eur J Med Chem 39:345-357.
17. Kauffenstein G, Bergmeier W, Eckly A, Ohlmann P, Léon C, Cazenave JP, Nieswandt B, and Gachet C (2001) The P2Y(12) receptor induces platelet aggregation through weak activation of the α(IIb)β(3) integrin-a phosphoinositide 3-kinase-dependent mechanism. FEBS Lett 505:281-290.
18. Kim HS, Ohno M, Xu B, Kim HO, Choi Y, Ji XD, Maddileti S, Marquez VE, Harden TK, and Jacobson KA (2003) 2-Substitution of adenine nucleotide analogues containing a bicyclo[3.1.0]hexane ring system locked in a northern conformation: enhanced potency as P2Y1 receptor antagonists. J Med Chem 46:4974-4987.
19. Lenain N, Freund M, Léon C, Cazenave JP, and Gachet C (2003) Inhibition of localized thrombosis in P2Y1-deficient mice and rodents treated with MRS2179, a P2Y1 receptor antagonist. J Thromb Hemostasis 1:1144-1149.
20. Léon C, Freund M, Ravanat C, Baurand A, Cazenave JP, and Gachet C (2001) Key role of the P2Y(1) receptor in tissue factor-induced thrombin- dependent acute thromboembolism: studies in P2Y(1)-knockout mice and mice treated with a P2Y(1) antagonist. Circulation 103:718-723.
21. Léon C, Hechler B, Freund M, Eckly A, Vial C, Ohlmann P, Dierich A, LeMeur M, Cazenave JP, and Gachet C (1999) Defective platelet aggregation and increased resistance to thrombosis in purinergic P2Y(1) receptor-null mice. J Clin Investig 104:1731-1737.
22. Léon C, Ravanat C, Freund M, Cazenave JP, and Gachet C (2003) Differential involvement of the P2Y1 and P2Y12 receptors in platelet procoagulant activity. Arterioscler Thromb Vasc Biol 23:1941-1947.
23. Nandanan E, Jang SY, Moro S, Kim HO, Siddiqui MA, Russ P, Marquez VE, Busson R, Herdewijn P, Harden TK, et al. (2000) Synthesis, biological activity and molecular modeling of ribose-modified deoxyadenosine bisphosphate analogues as P2Y(1) receptor ligands. J Med Chem 43:829-842.
24. Niitsu Y, Jakubowski JA, Sugidachi A, and Asai F (2005) Pharmacology of CS-747 (prasugrel, LY640315), a novel, potent antiplatelet agent with in vivo P2Y12 receptor antagonist activity. Semin Thromb Hemostasis 31:184-194.
25. Nonne C, Lenain N, Hechler B, Mangin P, Cazenave JP, Gachet C, and Lanza F (2005) Importance of platelet phospholipase Cγ2 signaling in arterial thrombosis as a function of lesion severity. Arterioscler Thromb Vasc Biol 25:1293-1298.
26. Ohno M, Costanzi S, Kim HS, Kempeneers V, Vastmans K, Herdewijn P, Maddileti S, Gao ZG, Harden TK, and Jacobson KA (2004) Nucleotide analogues containing 2-oxa-bicyclo[2.2.1]heptane and l-alpha-threofuranosyl ring systems: interactions with P2Y receptors. Bioorg Med Chem 12:5619-5630.
27. Patrono C (2001) Aspirin: new cardiovascular uses for an old drug. Am J Med 110:62S-65S.
28. Ralevic V and Burnstock G (1998) Receptors for purines and pyrimidines. Pharmacol Rev 50:413-492.
29. Ravi RG, Kim HS, Servos J, Zimmermann H, Lee K, Maddileti S, Boyer JL, Harden TK, and Jacobson KA (2002) Adenine nucleotide analogues locked in a Northern methanocarba conformation: enhanced stability and potency as P2Y(1) receptor agonists. J Med Chem 45:2090-2100.
30. Savi P and Herbert JM (2005) Clopidogrel and ticlopidine: P2Y12 adenosine diphosphate-receptor antagonists for the prevention of atherothrombosis. Semin Thromb Hemostasis 31:174-183.
31. Van Gestel MA, Heemskerk JW, Slaaf DW, Reneman RS, and oude Egbrink MG (2003) In vivo involvement of ADP in thromboembolism through its receptors P2Y1 and P2Y12, XIX ISTH Meeting, Birmingham, UK. J Thromb Hemostasis, Abstract P0777.
32. van Giezen JJ and Humphries RG (2005) Preclinical and clinical studies with selective reversible direct P2Y12 antagonists. Semin Thromb J Thromb Hemostasis 31:195-204.
33. Waldo GL, Corbitt J, Boyer JL, Ravi G, Kim HS, Ji XD, Lacy J, Jacobson KA, and Harden TK (2002) Quantitation of the P2Y(1) receptor with a high affinity radiolabeled antagonist. Mol Pharmacol 62:1249-1257.